Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm

Next Previous
X
Search
Trial Profile

Evaluation of Ruxolitinib and Azacytidine Combination as a Therapy for Patients With Myelofibrosis and Myelodysplastic Syndrome/ Myeloproliferative Neoplasm

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Ruxolitinib (Primary)
  • Indications Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Jun 2024 Interim results(From 3/2013-10/2021, n=61 pts) evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2023 Results( data cutoff July 15, 2023 , n=52 ) evaluating the use of RUX-AZA in newly diagnosed or previously treated MDS/ MPN, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 04 Apr 2023 Planned End Date changed from 1 Mar 2024 to 30 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top